eShowcase: iPlan Flow
Software disentangles delivery efficacy from drug efficacy, improving trial results
Software disentangles delivery efficacy from drug efficacy, improving trial results
BrainLab AG (Chicago, IL) has developed a system that allows targeted drug delivery into the brain for treating tumors, a technology that the company says could improve the results of drug trials and ultimately enhance the chances of regulatory approval during trials.
iPlan Flow
iPlan Flow addresses a difficult challenge, since the tight coating of blood vessels protects the brain and prevents fluids from entering it. Delivering enough drug concentration to specific brain cells is therefore problematic due to varying fluid dynamics. The technology uses magnetic resonance imaging to develop a three-dimensional image of the patient's brain. Then, it calculates the drug's distribution patterns, enabling a surgeon to identify the proper locations to place fluid delivery catheters. Potential applications include chemotherapy, gene therapy, molecular-targeted therapy, immunotherapy, and radio-immunotherapy.
BrainLab AG, (800) 784-7700, www.brainlab.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
